Pituitary adenoma: Difference between revisions

	Pituitary adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pituitary adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural history, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pituitary adenoma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pituitary adenoma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pituitary adenoma
CDC on Pituitary adenoma
Pituitary adenoma in the news
Blogs on Pituitary adenoma
Directions to Hospitals Treating Pituitary adenoma
Risk calculators and risk factors for Pituitary adenoma

Revision as of 14:39, 21 January 2012

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

^ Template:Note label Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993) Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata. Annals of Internal Medicine 119 (3), 236-240.

@@ Line 36: / Line 36: @@
 ==[[Pituitary adenoma surgery|Surgery]]==
-Treatment options depend on the type of tumor and on its size:
-* '''[[Prolactinoma]]s''' are most often treated with [[bromocriptine]] or more recently, [[cabergoline]] which, unlike bromocriptine, decreases tumor size as well as alleviates symptoms, both dopamine agonists, and followed by serial imaging to detect any increase in size. Treatment where the tumor is large can be with [[radiation therapy]] or surgery, and patients generally respond well.  Efforts have been made to use a progesterone [[antagonist]] for the treatment of prolactinomas, but so far have not proved successful.
-* '''Thyrotrophic adenomas''' respond to [[Somatostatin|octreotide, a long-acting somatostatin analog]], in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.{{ref_label|thyrotrophic|1|a}}
 ==References==